Overview

A Multi-center 12-week Study of HMS5552 in T2DM

Status:
Completed

Trial end date:
2016-09-01

Target enrollment:

Participant gender:

Summary

This study evaluates the safety, tolerability, efficacy and population PK of HMS5552 in type 2 diabetic adult subjects,there will be 5 groups ,4 groups will receive HMS5552,while 1 will receive placebo.

Phase:

Phase 2

Details

Lead Sponsor:

Hua Medicine Limited

Collaborator:

Tigermed Consulting Co., Ltd